Guobang Pharma (605507.SH) subsidiary product purified dimyristin glycerol ester passes CDE joint review and approval with the formulation

Zhitong Finance APP News, Guobang Pharma (605507.SH) announced that the company recently learned from the "Raw and Auxiliary Materials Registration Information" platform of the Center for Drug Evaluation (CDE) of the National Medical Products Administration that the pharmaceutical excipient "PEG-8 Distearate (for injection)" submitted by its wholly-owned subsidiary Zhejiang Guobang Pharmaceutical Co., Ltd. has received an "A" result in the CDE joint review and approval with the formulation.